explore -WSS

explore

author：hotspot 2025-09-30 14:58:36 - browse：114

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Wellcome Trust names Røttingen as its new CEO

knowledge

focus

WSS

Faced with fears of OxyContin misuse, sales reps touted its safety

White House drug shortages task force keeps mum with Congress

Large hospital system sues Multiplan for low

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

A fraught question for the kids of Alzheimer’s: Is it coming for us?

What's changing in Medicare's open enrollment this year?

explore

explore

entertainment

Moonlake's readout produced a cash windfall. Risks remain

Nick Jonas talks about managing diabetes along with his career

The cancer drug shortage isn’t new — and neither are the solutions

Where are patients getting their prescriptions for GLP

Medicare details structure of new drug price negotiation program

How should state employee insurance handle Wegovy?

State Dept. review finds Biden bears some blame for Afghanistan failures

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Sports medicine is finally prioritizing gender equality

Where are patients getting their prescriptions for GLP

knowledge

CDC overhauls leadership of center that led response to Covid

Novo acquires Inversago for up to $1 billion

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Wellcome Trust names Røttingen as its new CEO

Kim Kardashian sparks debate on benefits of full

An innovative path out of biotech’s “valley of death”

knowledge

focus

entertainment

leisure time